Is MAZE or SRRK more profitable?

Maze Therapeutics' return on equity of -36.62% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -36.62% -31.78% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to MAZE or SRRK?

In the previous week, Scholar Rock had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for Scholar Rock and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat Scholar Rock's score of 1.57 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Scholar Rock 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is MAZE or CGON more profitable?

CG Oncology's return on equity of -23.33% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -36.62% -31.78% CG Oncology N/A -23.33% -22.24%

Does the media favor MAZE or CGON?

In the previous week, CG Oncology had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for CG Oncology and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat CG Oncology's score of 1.02 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, MAZE or GRFS?

Grifols has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maze Therapeutics $20M 73.08 -$131.12M -$2.53 N/A Grifols $8.51B 0.57 $454.82M $0.19 37.79

Is MAZE or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Maze Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -36.62% -31.78% Grifols 5.54% 6.21% 2.39%

Does the media favor MAZE or GRFS?

In the previous week, Grifols had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 4 mentions for Grifols and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat Grifols' score of 0.39 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Grifols 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MAZE or AMRX?

In the previous week, Maze Therapeutics and Maze Therapeutics both had 2 articles in the media. Maze Therapeutics' average media sentiment score of 1.67 beat Amneal Pharmaceuticals' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amneal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is XENE or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -49.23% -46.42% Maze Therapeutics N/A -36.62% -31.78%

Does the media prefer XENE or MAZE?

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 3 mentions for Xenon Pharmaceuticals and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat Xenon Pharmaceuticals' score of 1.61 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Maze Therapeutics (MAZE) Competitors

$26.41 +0.84 (+3.29%)

Closing price 04:00 PM Eastern

Extended Trading

$25.79 -0.62 (-2.34%)

As of 07:58 PM Eastern

Compare

MAZE vs. SRRK, CGON, GRFS, AMRX, and XENE

Should you buy Maze Therapeutics stock or one of its competitors? MarketBeat compares Maze Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maze Therapeutics include Scholar Rock (SRRK), CG Oncology (CGON), Grifols (GRFS), Amneal Pharmaceuticals (AMRX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does Maze Therapeutics compare to Scholar Rock?

Maze Therapeutics (NASDAQ:MAZE) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

91.1% of Scholar Rock shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Maze Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Scholar Rock had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for Scholar Rock and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat Scholar Rock's score of 1.57 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Scholar Rock	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Maze Therapeutics' return on equity of -36.62% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Scholar Rock	N/A	-163.52%	-96.67%

Maze Therapeutics currently has a consensus target price of $66.00, indicating a potential upside of 149.91%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 9.23%. Given Maze Therapeutics' higher probable upside, research analysts clearly believe Maze Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Maze Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$20M	73.08	-$131.12M	-$2.53	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Summary

Maze Therapeutics beats Scholar Rock on 9 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to CG Oncology?

Maze Therapeutics (NASDAQ:MAZE) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, CG Oncology had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for CG Oncology and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat CG Oncology's score of 1.02 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology's return on equity of -23.33% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
CG Oncology	N/A	-23.33%	-22.24%

Maze Therapeutics presently has a consensus price target of $66.00, suggesting a potential upside of 149.91%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 24.34%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Maze Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Maze Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

26.6% of CG Oncology shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Maze Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$20M	73.08	-$131.12M	-$2.53	N/A
CG Oncology	$5.07M	1,143.27	-$160.99M	-$2.33	N/A

Summary

Maze Therapeutics beats CG Oncology on 9 of the 16 factors compared between the two stocks.

How does Maze Therapeutics compare to Grifols?

Maze Therapeutics (NASDAQ:MAZE) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Maze Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market. Comparatively, Grifols has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

In the previous week, Grifols had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 4 mentions for Grifols and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat Grifols' score of 0.39 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics currently has a consensus target price of $66.00, suggesting a potential upside of 149.91%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 39.28%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Grifols has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$20M	73.08	-$131.12M	-$2.53	N/A
Grifols	$8.51B	0.57	$454.82M	$0.19	37.79

Grifols has a net margin of 5.54% compared to Maze Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Grifols	5.54%	6.21%	2.39%

Summary

Grifols beats Maze Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Amneal Pharmaceuticals?

Maze Therapeutics (NASDAQ:MAZE) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Maze Therapeutics currently has a consensus target price of $66.00, suggesting a potential upside of 149.91%. Amneal Pharmaceuticals has a consensus target price of $15.80, suggesting a potential downside of 5.16%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Maze Therapeutics and Maze Therapeutics both had 2 articles in the media. Maze Therapeutics' average media sentiment score of 1.67 beat Amneal Pharmaceuticals' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amneal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$20M	73.08	-$131.12M	-$2.53	N/A
Amneal Pharmaceuticals	$3.02B	1.76	$72.06M	$0.38	43.84

Amneal Pharmaceuticals has a net margin of 4.01% compared to Maze Therapeutics' net margin of 0.00%. Maze Therapeutics' return on equity of -36.62% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Maze Therapeutics has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Summary

Maze Therapeutics and Amneal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Xenon Pharmaceuticals currently has a consensus target price of $77.20, suggesting a potential upside of 41.37%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 149.91%. Given Maze Therapeutics' higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market.

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 3 mentions for Xenon Pharmaceuticals and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat Xenon Pharmaceuticals' score of 1.61 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Maze Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	703.89	-$345.91M	-$4.70	N/A
Maze Therapeutics	$20M	73.08	-$131.12M	-$2.53	N/A

Maze Therapeutics' return on equity of -36.62% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Maze Therapeutics	N/A	-36.62%	-31.78%

Summary

Maze Therapeutics beats Xenon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAZE vs. The Competition

Export

Metric	Maze Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.42B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-10.44	19.75	24.92	23.98
Price / Sales	73.08	331.30	528.51	109.04
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	3.58	8.29	10.79	6.50
Net Income	-$131.12M	$23.85M	$3.56B	$336.88M
7 Day Performance	10.69%	5.21%	1.67%	-0.22%
1 Month Performance	2.44%	2.19%	0.43%	0.77%
1 Year Performance	146.13%	60.99%	32.84%	31.57%

Maze Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAZE Maze Therapeutics	3.1638 of 5 stars	$26.41 +3.3%	$66.00 +149.9%	+128.7%	$1.42B	$20M	N/A	121	Positive News
SRRK Scholar Rock	2.1126 of 5 stars	$44.18 -1.1%	$56.00 +26.8%	+44.5%	$5.29B	N/A	N/A	140	Positive News
CGON CG Oncology	3.0881 of 5 stars	$59.56 +3.3%	$81.73 +37.2%	+159.3%	$5.25B	$4.04M	N/A	61	Insider Trade
GRFS Grifols	4.6679 of 5 stars	$7.64 +2.0%	$10.00 +30.9%	-17.0%	$5.20B	$8.51B	40.21	25,247	News Coverage Dividend Announcement
AMRX Amneal Pharmaceuticals	2.4941 of 5 stars	$16.20 -0.9%	$15.80 -2.5%	+106.0%	$5.17B	$3.05B	42.63	8,500	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAZE) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maze Therapeutics (MAZE) Competitors

MAZE vs. SRRK, CGON, GRFS, AMRX, and XENE

How does Maze Therapeutics compare to Scholar Rock?

Summary

How does Maze Therapeutics compare to CG Oncology?

Summary

How does Maze Therapeutics compare to Grifols?

Summary

How does Maze Therapeutics compare to Amneal Pharmaceuticals?

Summary

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maze Therapeutics (MAZE) Competitors

MAZE vs. SRRK, CGON, GRFS, AMRX, and XENE

How does Maze Therapeutics compare to Scholar Rock?

Do insiders & institutionals hold more shares of MAZE or SRRK?

Which has more volatility & risk, MAZE or SRRK?

Does the media refer more to MAZE or SRRK?

Is MAZE or SRRK more profitable?

Do analysts rate MAZE or SRRK?

Which has higher earnings & valuation, MAZE or SRRK?

Summary

How does Maze Therapeutics compare to CG Oncology?

Does the media favor MAZE or CGON?

Is MAZE or CGON more profitable?

Do analysts prefer MAZE or CGON?

Which has more volatility & risk, MAZE or CGON?

Do insiders and institutionals have more ownership in MAZE or CGON?

Which has preferable earnings and valuation, MAZE or CGON?

Summary

How does Maze Therapeutics compare to Grifols?

Which has more risk & volatility, MAZE or GRFS?

Does the media favor MAZE or GRFS?

Do analysts prefer MAZE or GRFS?

Which has stronger valuation and earnings, MAZE or GRFS?

Is MAZE or GRFS more profitable?

Summary

How does Maze Therapeutics compare to Amneal Pharmaceuticals?

Do analysts recommend MAZE or AMRX?

Does the media favor MAZE or AMRX?

Which has better earnings & valuation, MAZE or AMRX?

Is MAZE or AMRX more profitable?

Do insiders and institutionals hold more shares of MAZE or AMRX?

Which has more volatility and risk, MAZE or AMRX?

Summary

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Do insiders & institutionals have more ownership in XENE or MAZE?

Do analysts recommend XENE or MAZE?

Which has more risk & volatility, XENE or MAZE?

Does the media prefer XENE or MAZE?

Which has stronger valuation & earnings, XENE or MAZE?

Is XENE or MAZE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools